Biomarker & Intervention Discovery

Tinnitus

This page lists 8 druggable gene targets, 15 approved or trial-tested drug candidates and 13 recent clinical trials for Tinnitus, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

US DALYs176.4KWHO GHE 2021 · all ages
Global DALYs3.71MWHO GHE 2021 · worldwide
US mortality120 deaths/yrWHO GHE 2021
Global mortality760 deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionSpontaneous resolution in 50-60% of acute tinnitus (<3 months) without treatment; chronic tinnitus (>3 months): only…
Best-intervention remissionCognitive behavioural therapy (CBT): 50-60% reduction in tinnitus-related distress (not sound elimination); tinnitus…
Gap sizeVery large — no pharmacological treatment exists; CBT and TRT are evidence-based but massively under-accessed
Primary barrierbiological + access
Full remission profile →

Remission & chronicity

Spontaneous remission
Spontaneous resolution in 50-60% of acute tinnitus (<3 months) without treatment; chronic tinnitus (>3 months): only 10-15% spontaneous resolution; habituated tinnitus (not distressing) in 75% at 5 years but sound remains in most
Best-intervention remission
Cognitive behavioural therapy (CBT): 50-60% reduction in tinnitus-related distress (not sound elimination); tinnitus retraining therapy (TRT): 80% improvement in distress over 18 months; hearing aids for comorbid hearing loss: modest tinnitus reduction; sound therapy (masking): symptom relief without cure
Gap size
Very large — no pharmacological treatment exists; CBT and TRT are evidence-based but massively under-accessed
Primary barrier
biological + access
No effective pharmacotherapy exists (multiple drug classes tried and failed); sound therapy and CBT are the only evidence-based interventions but trained tinnitus therapists are scarce; most patients are told to 'live with it'; digital CBT for tinnitus (iCBT) emerging as scalable solution

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

GABRA1 302GRIA1 161GRIN1 188GRIN2B 236KCNQ2 117KCNQ3 17KCNQ4 39SLC6A4 234
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PICROTOXIN ? unclear Mechanistic
THIAMYLAL SODIUM ~ modulates Mechanistic
GANAXOLONE ~ modulates Mechanistic
BUTOBARBITAL ? unclear Mechanistic
CHLORDIAZEPOXIDE ~ modulates Mechanistic
CLOBAZAM ~ modulates Mechanistic
CLORAZEPATE ? unclear Mechanistic
TPA023 ~ modulates Mechanistic
ZK-93423 ? unclear Mechanistic
FLUMAZENIL ~ modulates Mechanistic 3.3 nM (Ki)
AMOBARBITAL ? unclear Mechanistic
PAGOCLONE ~ modulates Mechanistic
OXAZEPAM ~ modulates Mechanistic
TETRAHYDRODEOXYCORTICOSTERONE ~ modulates Mechanistic
METHOHEXITAL ? unclear Mechanistic
CLONAZEPAM ~ modulates Mechanistic
[3H]GABAZINE ↓ inhibits Mechanistic
FLURAZEPAM ? unclear Mechanistic
METHARBITAL ~ modulates Mechanistic
LORAZEPAM ~ modulates Mechanistic
RO4938581 ~ modulates Mechanistic
SECOBARBITAL ? unclear Mechanistic
BUTABARBITAL SODIUM ~ modulates Mechanistic
MIDAZOLAM HYDROCHLORIDE ~ modulates Mechanistic
SANDARACOPIMARIC ACID ? unclear Mechanistic
QUAZEPAM ~ modulates Mechanistic
PHENOBARBITAL ? unclear Mechanistic
PRIMIDONE ~ modulates Mechanistic
ISOGUVACINE ↑ activates Mechanistic
ZOLPIDEM TARTRATE ~ modulates Mechanistic
CHEMBL:CHEMBL2170369 ? unclear Mechanistic
ESTAZOLAM ~ modulates Mechanistic
TOPIRAMATE ~ modulates Mechanistic
ETHCHLORVYNOL ~ modulates Mechanistic
CLORAZEPATE DIPOTASSIUM ~ modulates Mechanistic
ZALEPLON ~ modulates Mechanistic
FLUNITRAZEPAM ~ modulates Mechanistic 4.5 nM (Kd)
BUTABARBITAL ? unclear Mechanistic
THIAMYLAL ? unclear Mechanistic
BUTALBITAL ~ modulates Mechanistic

Showing top 40 of 302 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
PIRACETAM ~ modulates Mechanistic
RECOMBINANT FIBROBLAST GROWTH FACTOR 2 ? unclear Mechanistic
ANIRACETAM ~ modulates Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
NBQX ↓ inhibits Mechanistic 1600.0 nM (Ki)
HALOPERIDOL DECANOATE ? unclear Mechanistic
GYKI53655 ↓ inhibits Mechanistic
SELURAMPANEL ↓ inhibits Mechanistic
PHENOBARBITAL ? unclear Mechanistic
ARGIOTOXIN ↓ inhibits Mechanistic
MK-8777 ~ modulates Mechanistic
TALAMPANEL ↓ inhibits Mechanistic
PERAMPANEL ↓ inhibits Mechanistic 1180.0 nM (IC50)
FARAMPATOR ~ modulates Mechanistic
ISOFLURANE ? unclear Mechanistic
LY503430 ~ modulates Mechanistic
TEZAMPANEL ↓ inhibits Mechanistic
PESAMPATOR ~ modulates Mechanistic
CX516 ~ modulates Mechanistic
OSAVAMPATOR ~ modulates Mechanistic
[3H]AMPA ↑ activates Mechanistic
DESFLURANE ? unclear Mechanistic
SEVOFLURANE ? unclear Mechanistic
CX-717 ? unclear Mechanistic
[3H]CNQX ↓ inhibits Mechanistic
LY404187 ~ modulates Mechanistic
ASPARAGINE ? unclear Mechanistic
CYCLOTHIAZIDE ~ modulates Mechanistic 1000.0 nM (EC50)
S18986 ~ modulates Mechanistic
CX1739 ~ modulates Mechanistic
IDRA-21 ~ modulates Mechanistic
LY392098 ~ modulates Mechanistic
FLUORO-WILLARDIINE ↑ activates Mechanistic
GYKI53784 ↓ inhibits Mechanistic
ZONAMPANEL ↓ inhibits Mechanistic
ATPO ↓ inhibits Mechanistic
ANESTHETIC AGENT ? unclear Mechanistic
JORO SPIDER TOXIN ↓ inhibits Mechanistic
CX546 ~ modulates Mechanistic
DASOLAMPANEL ↓ inhibits Mechanistic

Showing top 40 of 161 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
AV-101 ↓ inhibits Mechanistic
COMPOUND 8 [PMID: 17562362} ↓ inhibits Mechanistic
KETAMINE HYDROCHLORIDE ~ modulates Mechanistic
SERINE, D- ↑ activates Mechanistic
5,7-DICHLOROKYNURENIC ACID ↓ inhibits Mechanistic
PHILANTHOTOXIN 343 ? unclear Mechanistic
FELBAMATE ↓ inhibits Mechanistic
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic
(+)-HA966 ↑ activates Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
AZD8108 ↓ inhibits Mechanistic
CNS-5161 ? unclear Mechanistic
D-SERINE ? unclear Mechanistic
GLYCINE ↑ activates Mechanistic
[3H]CGP39653 ↓ inhibits Mechanistic
EVT-101 ↓ inhibits Mechanistic
DEXANABINOL ? unclear Mechanistic
ORPHENADRINE ? unclear Mechanistic
TRAXOPRODIL ↓ inhibits Mechanistic
ESKETAMINE HYDROCHLORIDE ~ modulates Mechanistic
ESKETAMINE ~ modulates Mechanistic
MEMANTINE HYDROCHLORIDE ~ modulates Mechanistic
DELUCEMINE ↓ inhibits Mechanistic
[3H]L689560 ↓ inhibits Mechanistic
RALFINAMIDE ↓ inhibits Mechanistic
APIMOSTINEL ↑ activates Mechanistic
CYCLOSERINE ? unclear Mechanistic
[3H]CGP61594 ↓ inhibits Mechanistic
GW468816 ↓ inhibits Mechanistic
[3H]CPP ↓ inhibits Mechanistic
LATREPIRDINE ? unclear Mechanistic
NBQX ? unclear Mechanistic
[3H]CGS19755 ↓ inhibits Mechanistic
ORPHENADRINE HYDROCHLORIDE ↓ inhibits Mechanistic
[3H]D-ASPARTIC ACID ↑ activates Mechanistic
ORPHENADRINE CITRATE ↓ inhibits Mechanistic
(RS)-(TETRAZOL-5-YL)GLYCINE ↑ activates Mechanistic
DIZOCILPINE ? unclear Mechanistic
RADIPRODIL ↓ inhibits Mechanistic
PERZINFOTEL ↓ inhibits Mechanistic

Showing top 40 of 188 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
APIMOSTINEL ↑ activates Mechanistic
L701324 ↓ inhibits Mechanistic
FELBAMATE ↓ inhibits Mechanistic
METHYLPHENIDATE ? unclear Mechanistic
CLOZAPINE ? unclear Mechanistic
NVP-AAM077 ↓ inhibits Mechanistic
GLYCINE ↑ activates Mechanistic
SELFOTEL ↓ inhibits Mechanistic
AMANTADINE HYDROCHLORIDE ↓ inhibits Mechanistic
QUETIAPINE FUMARATE ? unclear Mechanistic
L689560 ↓ inhibits Mechanistic
LATREPIRDINE ? unclear Mechanistic
MG2+ ↓ inhibits Mechanistic
TRAXOPRODIL ↓ inhibits Mechanistic 74.0 nM (IC50)
VALPROIC ACID ? unclear Mechanistic
[3H]DIZOCILPINE ↓ inhibits Mechanistic
CNS-5161 ? unclear Mechanistic
NEBOGLAMINE ~ modulates Mechanistic
NP-10679 ? unclear Mechanistic
5,7-DICHLOROKYNURENIC ACID ↓ inhibits Mechanistic
GV196771A ↓ inhibits Mechanistic
DIZOCILPINE ↓ inhibits Mechanistic
INDANTADOL ↓ inhibits Mechanistic
ESKETAMINE HYDROCHLORIDE ~ modulates Mechanistic
SEVOFLURANE ? unclear Mechanistic
LANICEMINE ↓ inhibits Mechanistic
ASPARTIC ACID ↑ activates Mechanistic
UBP141 ↓ inhibits Mechanistic
DELUCEMINE ↓ inhibits Mechanistic
S-DESCHLOROKETAMINE ↓ inhibits Mechanistic
RAPASTINEL ↑ activates Mechanistic
[3H]L689560 ↓ inhibits Mechanistic
EVT-101 ? unclear Mechanistic
[3H]D-ASPARTIC ACID ↑ activates Mechanistic
[3H]MDL105519 ↓ inhibits Mechanistic
ELIPRODIL ? unclear Mechanistic 13.0 nM (Ki)
D-CCPENE ↓ inhibits Mechanistic
N1-DANSYL-SPERMINE ↓ inhibits Mechanistic
ESKETAMINE ~ modulates Mechanistic
KETAMINE HYDROCHLORIDE ↓ inhibits Mechanistic

Showing top 40 of 236 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
EZOGABINE ↑ activates Mechanistic 350.0 nM (EC50)
ICA-27243 ↑ activates Mechanistic
FLUPIRTINE ↑ activates Mechanistic
(S)-N-[1-(3-MORPHOLIN-4-YL-PHENYL)-ETHYL]-3-PHENYL-ACRYLAMIDE ↑ activates Mechanistic
GUANIDINE HYDROCHLORIDE ↓ inhibits Mechanistic
ICA-069673 ↑ activates Mechanistic
ML252 ↓ inhibits Mechanistic
PYRITHIONE ZINC ↑ activates Mechanistic
TETRAMETHYLAMMONIUM ↓ inhibits Mechanistic
TEDISAMIL ↓ inhibits Mechanistic
XE991 ↓ inhibits Mechanistic
QO-58 ↑ activates Mechanistic
ICA-105665 ? unclear Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
CELECOXIB ? unclear Mechanistic
AZETUKALNER ↑ activates Mechanistic 98.0 nM (EC50)
AMIFAMPRIDINE PHOSPHATE ↓ inhibits Mechanistic
PIP2 ↑ activates Mechanistic
DALFAMPRIDINE ↓ inhibits Mechanistic
LINOPIRDINE ↓ inhibits Mechanistic
FLINDOKALNER ↑ activates Mechanistic 2400.0 nM (EC50)
L735821 ↓ inhibits Mechanistic
AMIFAMPRIDINE ↓ inhibits Mechanistic
CHEMBL317935 ↑ activates Mechanistic 3000.0 nM (EC50)
CHEMBL100379 ↑ activates Mechanistic 1200.0 nM (EC50)
CHEMBL2164048 ↓ inhibits Mechanistic 70.0 nM (IC50)
CHEMBL2163678 ↑ activates Mechanistic 27420.0 nM (EC50)
CHEMBL2163670 ↑ activates Mechanistic 7090.0 nM (EC50)
CHEMBL2163668 ↑ activates Mechanistic 8660.0 nM (EC50)
CHEMBL2163666 ↑ activates Mechanistic 1020.0 nM (EC50)
CHEMBL2163686 ↓ inhibits Mechanistic 14990.0 nM (IC50)
CHEMBL2163350 ↓ inhibits Mechanistic 5270.0 nM (IC50)
CHEMBL2163673 ↓ inhibits Mechanistic 12670.0 nM (IC50)
CHEMBL2163667 ↓ inhibits Mechanistic 210.0 nM (IC50)
CHEMBL2163681 ↑ activates Mechanistic 12270.0 nM (EC50)
CHEMBL2163663 ↑ activates Mechanistic 800.0 nM (EC50)
CHEMBL1729184 ↑ activates Mechanistic 1750.0 nM (EC50)
CHEMBL2163660 ↑ activates Mechanistic 170.0 nM (EC50)
CHEMBL1320944 ↑ activates Mechanistic 2350.0 nM (EC50)
CHEMBL1572950 ↑ activates Mechanistic 350.0 nM (EC50)

Showing top 40 of 117 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
LINOPIRDINE ? unclear Mechanistic
AZETUKALNER ↑ activates Mechanistic
JNJ-37822681 ↑ activates Mechanistic
AMIFAMPRIDINE ↓ inhibits Mechanistic
TEDISAMIL ↓ inhibits Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
TETRAMETHYLAMMONIUM ↓ inhibits Mechanistic
GUANIDINE HYDROCHLORIDE ↓ inhibits Mechanistic
ICA-105665 ? unclear Mechanistic
AMIFAMPRIDINE PHOSPHATE ↓ inhibits Mechanistic
GABAPENTIN ↑ activates Mechanistic
DALFAMPRIDINE ↓ inhibits Mechanistic
FLINDOKALNER ↑ activates Mechanistic 2400.0 nM (EC50)
EZOGABINE ↑ activates Mechanistic 3900.0 nM (EC50)
CELECOXIB ? unclear Mechanistic
CHEMBL4545892 ↑ activates Mechanistic 10500.0 nM (EC50)
CHEMBL4457044 ↑ activates Mechanistic 920.0 nM (EC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AMIFAMPRIDINE ↓ inhibits Mechanistic
GUANIDINE HYDROCHLORIDE ↓ inhibits Mechanistic
XE991 ↓ inhibits Mechanistic
(S)-N-[1-(3-MORPHOLIN-4-YL-PHENYL)-ETHYL]-3-PHENYL-ACRYLAMIDE ↑ activates Mechanistic
FLINDOKALNER ↑ activates Mechanistic 2400.0 nM (EC50)
ML252 ↓ inhibits Mechanistic
AMIFAMPRIDINE PHOSPHATE ↓ inhibits Mechanistic
NC00075159 ↑ activates Mechanistic
RETIGABINE DERIVATIVE 10G ↑ activates Mechanistic
PIP2 ↑ activates Mechanistic
TETRAMETHYLAMMONIUM ↓ inhibits Mechanistic
TEDISAMIL ↓ inhibits Mechanistic
CELECOXIB ? unclear Mechanistic
ML213 ↑ activates Mechanistic
ICA-105665 ? unclear Mechanistic
BEPRIDIL ↓ inhibits Mechanistic
PYRITHIONE ZINC ↑ activates Mechanistic
DALFAMPRIDINE ↓ inhibits Mechanistic
NERISPIRDINE ↓ inhibits Mechanistic
LINOPIRDINE ↓ inhibits Mechanistic
EZOGABINE ↑ activates Mechanistic 5900.0 nM (EC50)
CHEMBL2164048 ↓ inhibits Mechanistic 200.0 nM (IC50)
CHEMBL3621437 ↑ activates Mechanistic 625.0 nM (EC50)
CHEMBL4287894 ↑ activates Mechanistic 100.0 nM (EC50)
CHEMBL4288707 ↑ activates Mechanistic 160.0 nM (EC50)
CHEMBL4287478 ↑ activates Mechanistic 4000.0 nM (EC50)
CHEMBL4277250 ↑ activates Mechanistic 20.0 nM (EC50)
CHEMBL1703636 ↑ activates Mechanistic 1600.0 nM (EC50)
CHEMBL4448132 ↑ activates Mechanistic 890.0 nM (EC50)
CHEMBL4450214 ↑ activates Mechanistic 2030.0 nM (EC50)
CHEMBL4588394 ↑ activates Mechanistic 780.0 nM (EC50)
CHEMBL4438770 ↑ activates Mechanistic 1420.0 nM (EC50)
CHEMBL4545892 ↑ activates Mechanistic 100.0 nM (EC50)
CHEMBL4457044 ↑ activates Mechanistic 80.0 nM (EC50)
CHEMBL5200636 ↑ activates Mechanistic 320.0 nM (EC50)
CHEMBL4458793 ↑ activates Mechanistic 910.0 nM (EC50)
CHEMBL5185685 ↑ activates Mechanistic 87.0 nM (EC50)
CHEMBL4549229 ↑ activates Mechanistic 660.0 nM (EC50)
CHEMBL5178988 ↑ activates Mechanistic 6400.0 nM (EC50)
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLOMIPRAMINE ↓ inhibits Mechanistic 70.0 nM (IC50)
CITALOPRAM ↓ inhibits Mechanistic 1.6 nM (Ki)
FLUVOXAMINE ↓ inhibits Mechanistic
MILNACIPRAN ↓ inhibits Mechanistic
PHENELZINE ↓ inhibits Mechanistic
FLUOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic
3,4-METHYLENEDIOXYMETHAMPHETAMINE ? unclear Mechanistic
BL-1021 ? unclear Mechanistic
FLUVOXAMINE MALEATE ? unclear Mechanistic
VENLAFAXINE ↓ inhibits Mechanistic 8.9 nM (Kd)
DESVENLAFAXINE FUMARATE ↓ inhibits Mechanistic
DESVENLAFAXINE SUCCINATE ↓ inhibits Mechanistic
NORTRIPTYLINE ↓ inhibits Mechanistic
ACETAMINOPHEN ? unclear Mechanistic
FAXELADOL ↓ inhibits Mechanistic
TEDATIOXETINE ? unclear Mechanistic
MINAPRINE ? unclear Mechanistic
TRAZODONE ? unclear Mechanistic
SERTRALINE HYDROCHLORIDE ↓ inhibits Mechanistic
LIAFENSINE ↓ inhibits Mechanistic
DAPOXETINE ↓ inhibits Mechanistic
MAZINDOL ↓ inhibits Mechanistic 50.0 nM (Ki)
VORTIOXETINE HYDROBROMIDE ↓ inhibits Mechanistic
COCAINE ? unclear Mechanistic 270.0 nM (IC50)
DULOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic
PAROXETINE HYDROCHLORIDE, HEMIHYDRATE ↓ inhibits Mechanistic
NORTRIPTYLINE HYDROCHLORIDE ↓ inhibits Mechanistic
TRIMIPRAMINE ↓ inhibits Mechanistic
LUMATEPERONE ↓ inhibits Mechanistic
AMITIFADINE ↓ inhibits Mechanistic
NEFAZODONE ↓ inhibits Mechanistic 200.0 nM (Kd)
ATOMOXETINE HYDROCHLORIDE ↓ inhibits Mechanistic
CHLORPHENTERMINE HYDROCHLORIDE ? unclear Mechanistic
TRAZODONE HYDROCHLORIDE ↓ inhibits Mechanistic
DEXFENFLURAMINE ? unclear Mechanistic
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic
N-DESMETHYLCLOZAPINE ? unclear Mechanistic
IBOGAINE ↓ inhibits Mechanistic
LEVOMILNACIPRAN ↓ inhibits Mechanistic
PSEUDOEPHEDRINE POLISTIREX ? unclear Mechanistic

Showing top 40 of 234 agents ranked by evidence tier.


Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Tinnitus: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

NCT05650645 Phase: 2 Started: 2023-01-01

Tinnitus is a persistent non-physiologic, non-psychiatric, ringing in the ear that affects up to 20% of the general US population. The purpose of this study is to assess the patient reported effectiveness of Xeomin (incobotulinumtoxinA) injections into the auricular muscles for relief of tinnitus wi...

NCT04066348 Phase: 2 Started: 2022-07-01

The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and/or noise exposure or associated with Traumatic Brain Injury (TBI) and/or concussion. Individua...

NCT07772089 Phase: 1/2 Started: 2026-03-25

This study tested whether a single dose of nicotine gum can reduce the loudness of tinnitus (ringing in the ears) in non-smoking adults with chronic tinnitus. Nicotine acts on brain nicotinic acetylcholine receptors that regulate the balance of excitation and inhibition in auditory and attention net...

NCT07190482 Phase: 1 Started: 2023-10-01

This research aims to evaluate the effects of the drug olanzapine on the discomfort caused by tinnitus according to each patient's personality traits. Olanzapine is a drug used as an antipsychotic whose mechanism of action makes it potentially useful for the treatment of tinnitus.

NCT04404439 Phase: 4 Started: 2019-09-26

Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. In addition, it contributes significant costs to the healthcare system. However, the mechanisms of tinnitus are poorly unde...

NCT05645432 Phase: 2 Started: 2023-05-10

The primary objective of this study is to evaluate the safety and tolerability of brexanolone in participants with tinnitus following a single 6-hour continuous intravenous (IV) infusion.

NCT07153991 Phase: 4 Started: 2021-11-19

This study is a prospective, placebo-controlled, randomized, double-blind clinical trial, including 70 patients with chronic sensorineural tinnitus, divided into placebo and treatment groups. Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily f...

NCT05591144 Phase: N/A Started: 2022-10-30

The goal of this clinical trial is to investigate the efficacy of oral steroids in the acute tinnitus population. Participants will receive appropriate dosages of short-term prednisone and/or oral Ginkgo Biloba tablets.

NCT04829214 Phase: 2 Started: 2021-03-22

The purpose of this study is to determine the efficacy of OTO-313 in subjects with unilateral tinnitus and to determine the safety and tolerability of OTO-313 in subjects with unilateral tinnitus.

NCT03918109 Phase: 1/2 Started: 2019-04-04

The purpose of this study is to evaluate the safety, tolerability, plasma pharmacokinetics (PK), and exploratory efficacy of OTO-313 administered as an intratympanic injection for the treatment of subjective tinnitus.

NCT03674853 Phase: N/A Started: 2018-06-12

To evaluate the effect of psychological/mental factors on the severity of subjective tinnitus, to observe the efficacy and safety of Wuling capsule in the treatment of chronic subjective tinnitus with emotional disorders, and to evaluate the control rate of tinnitus complications, such as depression...

NCT04105426 Phase: 2 Started: 2019-01-10

The purpose of this study is to assess the effectiveness of antioxidant supplementation in idiopathic tinnitus patients. To investigate this, a double-blind, randomized, and placebo-controlled clinical trial was conducted to assess the impact of a multivitamin-multimineral supplement with phytochemi...

NCT03365011 Phase: 4 Started: 2016-10

Tinnitus is perception of sound without the presence of an external acoustic stimulus. Approximately 50 million Americans experience chronic tinnitus and of these, 10 million have bothersome tinnitus. The tinnitus research literature suggests that NMDA receptor antagonists may prove to be useful in ...


Agents Found By Disease-Level Search

Searched directly from “Tinnitus” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

15 agents shown (approved or with trial evidence) — 12 not found by the gene-target search above.

Nortriptyline

· 1 trial · source: ClinicalTrials.gov
NCT06799169

Topiramate

· 1 trial · source: ClinicalTrials.gov
NCT06799169

Paroxetine

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06799169

VerapamilNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06799169

SPI-1005 Ebselen 200mg Capsule x1NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02819856

SPI-1005 Ebselen 200mg Capsule x2NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02819856

SPI-1005 Ebselen 200mg Capsule x3NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02819856

Transdermal LidocaineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02088866

Tele-PTMNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01129141

Wait List ControlNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01129141

SulodexideNOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02737670

AcetazolamideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01003639

MethylprednisolonNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05851508

AUT00063NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02315508

Levitra (Vardenafil, BAY38-9456)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00666809

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.